Discovery of a Novel, Potential First-In-Class Malt1 Protease Inhibitor for the Treatment of B Cell Lymphomas

Hematological Oncology - United Kingdom
doi 10.1002/hon.88_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment

Biomedical Sciences
2017English

Emerging Treatment Options for B-Cell Lymphomas

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2015English

The Discovery and Development of Boceprevir: A Novel, First-Generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease

Journal of Clinical and Translational Hepatology
2013English

A New Class of Serine and Cysteine Protease Inhibitor With Chemotherapeutic Potential.

1998English

Venetoclax Synergizes With Radiotherapy for Treatment of B-Cell Lymphomas

Cancer Research
Cancer ResearchOncology
2017English

Ruxolitinib Treatment and Risk of B‐cell Lymphomas in Myeloproliferative Neoplasms

American Journal of Hematology
Hematology
2019English

Liposomes Modified by Carbohydrate Ligands Can Target B Cells for the Treatment of B-Cell Lymphomas

Expert Review of Vaccines
Molecular MedicineDrug DiscoveryImmunologyPharmacology
2010English

Novel Insights Into the Disease Dynamics of B-Cell Lymphomas in the Genomics Era

Journal of Pathology
Forensic MedicinePathology
2018English

671 Discovery of LEO 39652 a Novel PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy